page header

Contents  ·  Introduction  ·  Learning  Objectives  ·  Textbook  ·  Lectures  ·  Procedures  ·  Final Exam  ·  Library  ·  Laboratory  ·  Pharmacy  ·  Imaging  ·  Forms  ·  Videos  ·  About  ·  Contact Us>

Heparin (Liquaemin)

Category:

  • Miscellaneous

Description:

  • Anticoagulant

Indications:

  • Venous thrombosis, pulmonary embolism, peripheral arterial embolism

  • Coagulopathies, DVT/PE prophylaxis, clotting prevention in arterial and heart surgery

  • Blood transfusions, extracorporeal circulation, dialysis and blood samples

Contraindications:

  • Severe thrombocytopenia, uncontrolled bleeding (except when due to DIC)

  • Suspected intracrainial hemorrhage, shock, severe hypotension

Precautions:

  • Pregnancy category C; does not cross placental barrier; not excreted in breast milk

  • IM injection (avoid due to risk for hematoma)

  • Elderly, children, diabetes,  renal insufficiency, severe hypertension

  • Subacute bacterial endocarditis, acute nephritis, peptic ulcer disease, sever renal disease

Adverse Reactions (Side Effects):

  • CNS: fever, rash

  • CV: allergic vasospastic reactions, shock

  • EENT: lacrimation, rhinitis

  • GI: nausea, vomiting

  • GU: hematuria, priapism

  • HEME: hemorrhage, thrombocytopenia, white clot syndrome

  • RESP: anaphylactoid reactions, asthma

  • SKIN: chills, cutaneous necrosis, delayed transient alopecia, erythema, histamine-like reactions, local irritation, urticaria

Dosage:

Administered SC and IV

  • Adult:            

    • DVT/PE: 

      • IV INF 50-100 u/kg initially, then 15-25 u/kg/hr, adjusted based on APTT results; intermittent IV 10,000u initially, then 75-125 u/kg every 4-6 hours

      • SC 10,000-20,000u initially, then 8,000-10,000u every 8 hours or 15,000-20,000u every 12 hours

    • Prevent DVT/PE: 

      • SC 5000u every 8-12 hours until patient is ambulatory

  • Child:   

    • IV INF 50 u/kg initially, then 15-25 u/kg/hr, increase dose by 2-4 u/kg/hr every 6-8 hours based on aPTT results

    • Intermittent IV 50-100 u/kg initially, then 50-100 u/kg every 4 hours

 


The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks

Source: Operational Medicine 2001,  Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300

This information is provided by The Brookside Associates.  The Brookside Associates, LLC. is a private organization, not affiliated with any governmental agency. The opinions presented here are those of the author and do not necessarily represent the opinions of the Brookside Associates or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. All material presented here is unclassified.

C. 2009, 2014, All Rights Reserved

brookside associates logo

 

 

 

 

 

 

Advertise on this site